UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 20, 2023
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
| delaware | | 001-39717 | | 20-2903526 |
| (State or other jurisdiction | | (Commission | | (IRS Employer |
| of incorporation) | | File Number) | | Identification No.) |
680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
(Address of principal executive offices)
(631) 830-7092
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | | LIXT | | The Nasdaq Stock Market, LLC |
| Warrant to Purchase Common Stock, par value $0.0001 per share | | LIXTW | | The Nasdaq Stock Market, LLC |
Item 8.01. Other Events.
Reference is made to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 20, 2023 in connection with the Registered Offering. The Registered Offering closed on July 20, 2023. The Company issued a press release with respect to the closing of the Registered Offering on July 20, 2023. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) There are filed as part of this report the exhibits listed on the accompanying Index to Exhibits which exhibit is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 21, 2023 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
| | |
| | By: | /s/ JOHN S. KOVACH |
| | | John S. Kovach, |
| | | Chief Executive Officer |
INDEX TO EXHIBITS
